Itraconazole

證據等級: L5

預測適應症: 1 個

Itraconazole: From Fungal Infections to Pneumocystosis

One-Sentence Summary

Itraconazole is a broad-spectrum triazole antifungal agent widely used to treat systemic and superficial fungal infections including aspergillosis, histoplasmosis, and onychomycosis. The TxGNN model predicts it may be effective for Pneumocystosis (infection caused by Pneumocystis jirovecii), with 0 clinical trials and 20 publications identified — however, critical mechanistic evidence strongly contradicts this prediction.

Quick Overview

Item	Content
Original Indication	Systemic and superficial fungal infections (aspergillosis, histoplasmosis, onychomycosis, etc.)
Predicted New Indication	Pneumocystosis (Pneumocystis jirovecii pneumonia, PCP)
TxGNN Prediction Score	99.34%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Itraconazole belongs to the triazole antifungal class and exerts its effect by inhibiting lanosterol 14α-demethylase (CYP51/Erg11), a key enzyme in the ergosterol biosynthesis pathway. By blocking ergosterol production, itraconazole disrupts fungal cell membrane integrity and function. This mechanism is highly effective against organisms whose cell membranes depend on ergosterol, such as Aspergillus, Histoplasma, and Candida species.

However, there is a fundamental mechanistic contradiction with this prediction: Pneumocystis jirovecii is a unique atypical fungus whose cell membrane lacks ergosterol entirely — it substitutes cholesterol instead. Because itraconazole’s target enzyme (Erg11) requires ergosterol as the downstream product, all azole antifungals and polyene antifungals (which also target ergosterol) are intrinsically ineffective against P. jirovecii. This is corroborated by the molecular study (PMID 12606318), which confirmed that the P. carinii Erg11 protein shares key amino acid substitutions associated with azole resistance.

The co-occurrence of itraconazole and pneumocystosis in the literature most likely reflects ecological association rather than therapeutic relevance: both conditions frequently arise in the same immunocompromised patient populations (HIV/AIDS, organ transplant recipients, patients on corticosteroids), not because itraconazole treats PCP. The first-line treatment for PCP remains TMP-SMX, with alternatives including pentamidine, atovaquone, and clindamycin + primaquine. This prediction is therefore considered a likely ecological fallacy in the TxGNN model output.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11737382	2001	RCT (double-blind, placebo-controlled)	HIV Medicine	Phase III trial of itraconazole prophylaxis in HIV-infected patients; evaluated prevention of deep fungal infections (not PCP specifically)
21418688	2010	Clinical Guideline / Review	BMJ Clinical Evidence	HIV opportunistic infection prophylaxis guidelines; PCP prophylaxis centres on TMP-SMX, not azoles
2121456	1990	Review	Drugs	Review of protozoan infection therapy including P. carinii; azoles not listed as treatment options
8016481	1993	Review	Seminars in Respiratory Infections	Lung transplant infections; PCP prophylaxis discussed without mention of itraconazole
8397916	1993	Review	Current Clinical Topics in Infectious Diseases	Bone marrow transplant antimicrobial prophylaxis; itraconazole mentioned for fungal coverage, not PCP
12606318	2003	Basic Science	Am J Respir Cell Mol Biol	Characterised P. carinii Erg11; confirmed inherent resistance to azoles due to specific amino acid substitutions — key mechanistic evidence against this repurposing
26036497	2015	Retrospective Cohort	Transplantation Proceedings	Invasive fungal infections post-kidney transplant; itraconazole used for mould coverage, PCP treated separately with TMP-SMX
30429396	2018	Observational Study	Indian Journal of Medical Microbiology	Respiratory fungal pathogens in immunocompromised vs. immunocompetent hosts; PCP and azole-susceptible fungi co-occur in same population
36891307	2023	Case Report	Frontiers in Immunology	Talaromyces marneffei + P. jirovecii co-infection in a child with STAT1 mutation; itraconazole used for talaromycosis, not PCP
8967681	1996	Case Report	Annals of Internal Medicine	Uveitis associated with rifabutin prophylaxis and itraconazole therapy in an HIV patient; highlights itraconazole DDI risk in this population

Safety Considerations

Drug Interactions (295 interactions identified; selected major and clinically significant interactions listed below):

Severity	Interacting Drug	Clinical Relevance
Major	Loperamide	Risk of serious cardiac events (QT prolongation / torsades de pointes)
Major	Triamcinolone	Itraconazole inhibits CYP3A4, markedly increasing corticosteroid exposure; risk of Cushing’s syndrome and adrenal suppression
Major	Budesonide	Same mechanism as triamcinolone; systemic budesonide levels can increase dramatically
Moderate	Omeprazole, Rabeprazole	Proton pump inhibitors reduce gastric acid → impaired absorption of itraconazole capsules
Moderate	Famotidine, Ranitidine, Cimetidine	H2 blockers reduce gastric acid → impaired itraconazole capsule absorption
Moderate	Dexamethasone, Hydrocortisone, Betamethasone	CYP3A4 inhibition increases corticosteroid exposure
Moderate	Aprepitant	Mutual CYP3A4 interaction; increased plasma levels of both agents
Moderate	Alosetron	Increased alosetron exposure via CYP3A4 inhibition
Moderate	Budesonide (nasal)	Systemic absorption risk via CYP3A4 inhibition
Minor	Metformin, Pioglitazone	Minor pharmacokinetic interactions; clinical significance generally low
Minor	Amphotericin B / Amphotericin B (lipid complex)	Potential antagonism; itraconazole may reduce ergosterol availability needed for amphotericin B binding

For complete warnings, contraindications, and special population guidance, please refer to the approved package insert, as this data was not available in the current Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high (99.34%), but this is a case where the model appears to have learned co-occurrence in immunocompromised populations rather than a genuine therapeutic relationship. The fundamental mechanistic barrier — P. jirovecii lacks ergosterol, the molecular target of all azole antifungals — makes itraconazole pharmacologically inactive against PCP. No clinical trials support this indication, and the existing literature does not contain evidence of itraconazole being used or studied as a PCP treatment.

To proceed (if further investigation is deemed warranted), the following is needed:

Mechanistic rebuttal investigation: Confirm whether any novel mechanism (e.g., host-directed therapy, immunomodulatory effects, or inhibition of cholesterol pathway in P. jirovecii) could theoretically justify activity independent of ergosterol targeting
Full package insert data: Retrieve TFDA/EMA/FDA prescribing information to complete safety assessment (key warnings, contraindications)
DrugBank MOA data: Formally confirm mechanism of action via DrugBank API to support or refute the mechanistic analysis above
Expert consultation: Obtain infectious disease specialist review before any further investment in this repurposing hypothesis
India regulatory pathway: If evidence were to emerge, note that itraconazole is currently not registered in India (0 licenses), requiring a full regulatory submission

⚠️ Research Note: This result is provided for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.